Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from HUTCHMED (China) ( (HK:0013) ).
HUTCHMED (China) Limited announced that as of November 28, 2025, its issued share capital consists of 872,169,670 ordinary shares, each carrying one voting right. This figure is significant for shareholders to determine their interest in HUTCHMED shares under the Financial Conduct Authority’s rules. The announcement provides clarity on the company’s share structure, which could impact shareholder decisions and market perceptions.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
See more data about 0013 stock on TipRanks’ Stock Analysis page.